Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MST1R | Q04912 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 16/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030467 | 0.90 | MST1R (0.57) | MST1RBRAFAXLEGFRMET | |
| SCHEMBL11030851 | 0.86 | MST1R (0.51) | MST1RBRAFAXLMET | |
| SCHEMBL11031317 | 0.86 | MST1R (0.51) | MST1RBRAFAXLMET | |
| SCHEMBL1160864 | 0.85 | MST1R (0.50) | MST1RBRAFAXL | |
| SCHEMBL11888386 | 0.85 | MST1R (0.50) | MST1RBRAFAXLBRD4EGFR | |
| SCHEMBL11028415 | 0.84 | MST1R (0.49) | MST1RAXLMET | |
| SCHEMBL1160924 | 0.84 | MST1R (0.49) | MST1RBRAFAXLEGFRMET | |
| SCHEMBL11886981 | 0.84 | MST1R (0.52) | MST1RAXLBRD4 | |
| SCHEMBL11033694 | 0.84 | AXL (0.48) | MST1RAXLBRD4 | |
| SCHEMBL11028985 | 0.84 | MST1R (0.48) | MST1RAXLBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | MST1R 2790/4885BRAF 582/4885AXL 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.